About Cristal Therapeutics

Cristal Therapeutics is a clinical stage pharmaceutical company.

Our mission is to create the next generation of targeted nanomedicines for improving the treatment of cancer and other diseases.

Our product candidates are centred on our proprietary polymeric nanoparticle construct called CriPec^®. They are rationally designed to target specific tissue, cells and intracellular components, and to have a defined duration at disease sites.

The Company’s lead drug candidate, CPC634 is in Phase 2 clinical studies for the treatment of solid tumours. It is an innovative CriPec^® version of docetaxel, a well-established, marketed chemotherapy drug. Results from Phase 1 studies have demonstrated that CPC634 has an enhanced safety and tolerability profile compared to standard docetaxel.

Cristal Therapeutics is led by a management team of entrepreneurial life science executives and supported by an industry-experienced Supervisory Board and internationally renowned Scientific Board.

Watch Informa interview with our CEO/CMO, Dr Axel Mescheder at BIOEurope 2018

Location

The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.

Investment

Cristal Therapeutics is a private company that has raised over €30M in equity investments and grant awards to date.

History

The company was founded by Cristianne Rijcken, PhD, and Joost Holthuis, PhD, in 2011 as a spin-off of the Department of Pharmaceutical Sciences of the Utrecht University, The Netherlands.

IP Position

Cristal Therapeutics has an extensive patent estate that includes seven patent families covering its CriPec^® platform and related products.